Core Viewpoint - The flu virus is becoming increasingly active in China as the autumn and winter temperatures drop, with the positive rate of flu-like cases nearing 45%, indicating a significant rise in respiratory infectious diseases [1] Group 1: Flu Activity and Prevention - The flu virus can spread through droplets and contact with contaminated surfaces, emphasizing the need for effective protective measures [1] - The Chinese Center for Disease Control and Prevention highlights the importance of hand protection in preventing the transmission of the flu virus [1] Group 2: Company Overview - Zhonghong Medical, a state-controlled listed company, is a leading player in the domestic medical protection sector, offering a comprehensive range of medical gloves to enhance health protection during the flu season [1][2] - The company provides various types of disposable protective gloves, including medical examination gloves and household protective gloves, catering to different scenarios from professional medical use to home care [2] Group 3: Product Features and Innovations - Zhonghong Medical's gloves are designed to meet industry standards and utilize innovative materials and processes to create a multi-layered hand protection system for flu prevention [2] - The company emphasizes the importance of proper glove usage, including the "one-use-one-change" principle, to minimize the risk of secondary contamination [2] Group 4: Future Focus and Product Expansion - In addition to disposable health protection gloves, Zhonghong Medical is expanding its product line to include condoms, safety infusion devices, wireless monitoring sensors, and other health-related products [2] - The company plans to focus on developing life support devices, surgical instruments, implantable devices, and assisted reproductive technology products in the future [2]

香港交易及結算所有限公司、香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容 概不負責，對其準確性或完整性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Shenzhen Mindray Bio-Medical Electronics Co., Ltd. 深圳邁瑞生物醫療電子股份有限公司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的要求 而刊發，僅用作提供資料予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即代表 閣 下知悉、接納並向本公司、本公司的聯席保薦人、整體協調人、顧問或承銷團成員表示同意： 本公司招股章程根據香港法例第32章《公司（清盤及雜項條文）條例》送呈香港公司註冊處處長登記前，本 公司不會向香港公眾人士提出要約或邀請。倘在適當時候向香港公眾人士提出要約或邀請，有意投資者務 請僅依據於香港公司註冊處處長註冊的本公司招股章程作出投資決 ...

Financial Performance - In the first three quarters of 2025, the company achieved revenue of 1.358 billion CNY, a year-on-year increase of 10.59% [3] - The third quarter alone generated revenue of 515 million CNY, reflecting a growth of 27.27% [3] - Net profit for the first three quarters reached 93.81 million CNY, up 12.75% year-on-year [3] - The net profit attributable to shareholders, excluding non-recurring gains and losses, was 85.43 million CNY, an increase of 12.53% [3] - The third quarter's net profit attributable to shareholders was 25.01 million CNY, showing a slight decline due to credit impairment losses [3] Medical Services Sector - The company focuses on high-quality and differentiated development, with a 10% increase in surgical volume overall [5] - The number of outpatient visits increased by 7%, while inpatient admissions rose by 20% [5] - Revenue from oncology services reached 415 million CNY, showing significant growth [5] - AI technology has been integrated into the entire medical service chain, improving diagnostic accuracy and operational efficiency [6][7] Medical Devices Sector - The domestic market share for infusion pumps surpassed 10%, ranking third in the industry [8] - Overseas revenue for medical devices grew by 29% year-on-year, with international business accounting for 30% of total revenue [8] Integration of Changsha Kexin Hospital - Since its integration, the hospital has performed over 7,000 minimally invasive surgeries, a year-on-year increase of 8% [9] - The proportion of out-of-province patients reached 40%, up 4 percentage points [9] - Patient volume increased by 11% post-integration, with outpatient visits also rising by 11% [10] AI Applications in Healthcare - AI imaging systems improved the detection rate of small metastatic lesions by 32% [11] - The time for a complete patient visit process was reduced from 2-3 days to within 1 day, with diagnostic times significantly shortened [11] - Patient satisfaction has improved due to AI-driven services addressing key pain points for late-stage cancer patients [12] Future Outlook - The company aims to enhance its AI capabilities to improve patient experience and operational efficiency [13][14] - There are plans for future acquisitions in the medical device sector to expand product offerings and market presence [18]

Core Viewpoint - Despite challenges such as trade protectionism and fluctuating tariff policies, China's foreign trade has shown resilience, with a reported 3.5% year-on-year growth in import and export value for the first eight months of the year [1][2]. Group 1: Trade Performance - In August, China's goods exports reached 2.3 trillion yuan, marking a 4.8% year-on-year increase, with exports to the U.S. accounting for 30% of total exports [2][5]. - The overall export value increased by 32% despite a 25% decline in exports to the U.S. during the first half of the year due to tariffs [2][3]. - For the first eight months, trade with ASEAN countries grew by 9.7%, while trade with the EU increased by 4.3% [3][8]. Group 2: Challenges Faced - The foreign trade sector is facing significant challenges, including unclear tariff policies, increasing order fragmentation, and intensified market competition [4][5]. - Exports to the U.S. have seen a 33.1% year-on-year decline in August, raising concerns about the impact of potential future tariffs [5][6]. - The shift towards smaller, fragmented orders has led to increased production costs and inefficiencies for many companies [6][7]. Group 3: Strategic Responses - Companies are diversifying their production bases to mitigate risks associated with tariffs, with some establishing factories in countries like Bangladesh, Vietnam, and Cambodia [3][7]. - A market diversification strategy is being adopted, with companies increasing their presence in emerging markets such as Southeast Asia and Latin America [3][8]. - Firms are investing in digital transformation and smart manufacturing to enhance flexibility and responsiveness to market demands [6][8]. Group 4: Future Outlook - There is optimism among foreign trade enterprises regarding future growth, particularly in markets where Chinese products are competitively priced [9]. - Companies are focusing on product diversification and high value-added offerings to strengthen their competitive edge [8][9].

Core Viewpoint - Despite the challenges posed by global economic recovery and trade protectionism, China's foreign trade has shown resilience, with a year-on-year growth of 3.5% in the first eight months of the year, reaching a total trade value of 29.57 trillion yuan [3][4]. Group 1: Resilience in Foreign Trade - The export value in August was 2.3 trillion yuan, marking a 4.8% year-on-year increase, with six consecutive months of growth [3][4]. - The decline in exports to the U.S. was significant, with a 25% drop in the first half of the year, yet overall exports still grew by 32% [3][4]. - Factors contributing to this resilience include the upgrading of industrial chains and product structures, a diversified market strategy, and supportive policies such as export credit insurance and tax rebates [3][4]. Group 2: Industry Adaptation Strategies - Companies are diversifying their production bases, with some establishing factories in countries like Bangladesh and Cambodia to mitigate tariff impacts [4]. - The market diversification strategy is being emphasized, as evidenced by increased exports to ASEAN and EU markets, which grew by 9.7% and 4.3% respectively in the first eight months [4]. - The shift towards smaller, faster orders has prompted companies to adopt smart manufacturing and digital transformation to enhance flexibility and efficiency [8]. Group 3: Challenges Ahead - Uncertainty in tariff policies, increasing order fragmentation, and intensified market competition are significant challenges facing the foreign trade sector [6][7]. - The export to the U.S. saw a 33.1% year-on-year decline in August, highlighting the impact of tariff uncertainties on business expectations [6][7]. - The shift to smaller orders has led to increased production costs and inefficiencies, particularly for companies that have not yet undergone technological upgrades [8]. Group 4: Future Directions - To address these challenges, a collaborative approach between policy and enterprises is essential, focusing on market and product diversification [10]. - Companies are encouraged to innovate trade models and enhance product value, particularly in high-value sectors like new energy and smart manufacturing [11]. - The emphasis on sustainable products is growing, with companies like Jida (Shanghai) Textile Co. planning to develop eco-friendly clothing to meet consumer demand for sustainability [11].

Core Viewpoint - Despite challenges such as tariff uncertainties and market competition, China's foreign trade has shown resilience, with a reported 3.5% year-on-year growth in total import and export value for the first eight months of the year, reaching 29.57 trillion yuan [1][2]. Group 1: Trade Performance - In August, China's goods exports amounted to 2.3 trillion yuan, marking a 4.8% year-on-year increase, with exports to the U.S. accounting for 30% of total exports [2][5]. - Although exports to the U.S. decreased by 25% in the first half of the year due to tariffs, overall exports still grew by 32% [2]. - For the first eight months, exports to ASEAN increased by 9.7%, while exports to the EU rose by 4.3% [3]. Group 2: Factors Supporting Growth - The resilience in foreign trade is attributed to three main factors: upgrading of industrial chains and product structures, effective market diversification strategies, and supportive government policies [2][3]. - The rapid growth of sectors like new energy vehicles, photovoltaics, and lithium batteries has contributed to this resilience [2]. - Policies such as export credit insurance, tax rebates, and special financing support have helped stabilize orders and cash flow for enterprises [2]. Group 3: Industry Adaptation - Companies are diversifying production bases to mitigate risks associated with tariffs, with some establishing factories in countries like Bangladesh, Vietnam, and Cambodia [3]. - The shift towards a market diversification strategy is evident, as companies increase their presence in emerging markets like Southeast Asia and Latin America [3][7]. - The implementation of smart manufacturing and digital transformation has enabled companies to adapt to the demand for smaller, faster orders, enhancing their competitive edge [6][8]. Group 4: Challenges Ahead - Despite the growth, challenges remain, including unclear tariff policies, increasing order fragmentation, and intensified market competition [4][5]. - The uncertainty surrounding tariffs has led to a decline in export orders, with companies experiencing a shift from large batch orders to smaller, more frequent orders [5][6]. - The competitive landscape is tightening, with companies needing to engage in price competition to maintain market share, particularly in the U.S. market [6][7]. Group 5: Strategic Recommendations - To address these challenges, companies are encouraged to focus on market and product diversification, enhancing their value chain positioning, and investing in technology and compliance capabilities [7][8]. - Establishing overseas warehouses and innovative trade models can help mitigate the impact of sudden tariff changes [7]. - Companies are increasingly looking to develop sustainable products to meet the growing consumer demand for environmentally friendly options [8]. Group 6: Future Outlook - Despite current challenges, companies remain optimistic about future growth opportunities, particularly in markets where Chinese products offer competitive advantages [9].

AI Medical Applications - The company has developed a three-layer AI+ medical framework, including IncGPT, data lakes, and various AI capabilities for diagnosis and treatment [1][2] - In the first half of the year, the average service volume per person increased by 10%, and the average length of stay in hospitals decreased by 3% and 9% for specific hospitals, enhancing bed turnover efficiency [2][3] - The company has reduced its expense ratio by 2 percentage points year-on-year through effective cost control [2] User Experience Enhancements - AI technology is being integrated into the entire diagnostic and treatment process to improve service efficiency and quality [3] - Specific applications include AI-driven pre-diagnosis recommendations, optimized in-hospital service processes, and AI-powered patient follow-up systems [3] Brain-Computer Interface Developments - The company has performed 23 deep brain stimulation surgeries for Parkinson's patients, utilizing advanced techniques to minimize side effects and improve patient outcomes [5] - Future plans include exploring the feasibility of brain-computer interface technologies for treating neurological diseases [5] Medical Device Performance - Overseas revenue from medical devices grew by 35% year-on-year, driven by user experience and product customization [6] - The company has expanded its distribution network by adding 9 new distributors across various regions [6] Oncology Business Growth - Oncology revenue reached 21,495.33 million yuan, a year-on-year increase of 25.14%, with significant growth in patient visits and advanced surgical procedures [8] - The company has received multiple recognitions and certifications for its oncology services, enhancing its industry influence [8][9] Market Position and Competitive Strategy - The company maintains a market share of over 10% in infusion pumps and mammography equipment, ranking third in both categories [10][11] - Strategies for maintaining competitiveness include high-end product upgrades and refined channel management, achieving over 40% coverage in top-tier hospitals [11] Differentiated Hospital Services - The company emphasizes quality, service, and environment, introducing new services such as weight management clinics and precision anti-aging solutions [12] - The company has integrated over 100 innovative applications to enhance clinical treatment levels across various specialties [12] Future AI Empowerment Plans - The company plans to leverage its AI capabilities to enhance the digital infrastructure of Changsha Kexin Hospital, improving patient services and operational efficiency [14]

Core Insights - Yingkang Life announced on August 26 that its key subsidiaries are Shengnuo Medical and Yuni Medical, with Shengnuo Medical achieving revenue of 97.23 million yuan in the first half of 2025, a year-on-year increase of 11.21%, and a net profit of 16.71 million yuan, up 28.70% [1] - Shengnuo Medical maintained its market share in a competitive environment, with a domestic market share of over 10% for infusion pumps, ranking third, and a similar ranking for mammography equipment with a market share of approximately 10% [1] - Yuni Medical reported revenue of 50.77 million yuan in the first half of 2025, a year-on-year increase of 12.59%, and a net profit of 15.58 million yuan, up 37.75% [1] - The collaboration between Shengnuo and Yuni has enabled the company to penetrate over 720 top-tier hospitals, achieving a coverage rate of over 40% in these hospitals [1]

Core Viewpoint - The company reported a steady growth in net profit for 1H25, driven by advancements in its medical services and medical devices segments, alongside effective cost reduction measures. The outlook for the full year remains positive with an expected net profit growth of 15% [1]. Group 1: Financial Performance - In 1H25, the company achieved revenue of 843 million yuan (+2.4% year-on-year) and a net profit attributable to shareholders of 62 million yuan (+12.8% year-on-year) [1]. - The second quarter saw a quarter-on-quarter increase in revenue and net profit of 6.08% and 6.14%, respectively [1]. - The gross profit margin improved by 0.5 percentage points year-on-year, while the expense ratio decreased by 2 percentage points [1]. Group 2: Medical Services Segment - The medical services segment generated revenue of 653 million yuan in 1H25 (+2.3% year-on-year), with a stable gross margin of 21.24% [2]. - The segment's growth was supported by a 25% year-on-year increase in tumor-related revenue [2]. - The integration of Changsha Kexin Hospital is expected to boost revenue in 2H25, with a profit target of no less than 57 million yuan for the year [2]. Group 3: Medical Devices Segment - The medical devices segment reported revenue of 190 million yuan in 1H25 (+2.8% year-on-year) with a slight increase in gross margin to 46.03% [3]. - The domestic market share for key products has been stable, with over 10% market share in infusion pumps and mammography equipment [3]. - The overseas business experienced a significant growth of 35% year-on-year, driven by a tailored strategy for different markets [3]. Group 4: Profit Forecast and Valuation - The company projects EPS for 2025-2027 to be 0.18, 0.21, and 0.23 yuan, reflecting a downward revision from previous estimates [4]. - A price-to-earnings ratio of 69 times is assigned for 2025, with a target price of 12.42 yuan, up from 11.97 yuan, due to positive expectations for the integration of Changsha Kexin [4].

Financial Performance - The company achieved revenue of 843 million CNY in the first half of 2025, a year-on-year increase of 2.40% [3] - Net profit attributable to shareholders reached 61.83 million CNY, up 12.82% year-on-year [3] - Medical services segment revenue was 653 million CNY, growing 2.28% year-on-year [3] - Medical device segment revenue was 190 million CNY, with a year-on-year increase of 2.80% [3] Oncology Services - Revenue from oncology services reached 215 million CNY, a significant increase of 25.14% [3] - The number of level IV surgeries increased by 6.62% [3] - The outpatient volume at Friendship Hospital reached 24,200 visits, up 21.59% year-on-year [3] - The proportion of level IV surgeries at Friendship Hospital increased by 8 percentage points [3] Medical Device Market - The company’s infusion pump market share exceeded 10%, ranking third in the domestic market [16] - The mammography device market share is approximately 10%, also ranking third [17] - Overseas revenue for medical devices grew by 35% year-on-year [18] AI Integration - AI applications have improved clinical capabilities, reducing complication rates by 10% and average hospital stays by 1-2 days [15] - The efficiency of image diagnosis increased by 66%, and patient follow-up efficiency improved by 300% [15] - Patient Net Promoter Score (NPS) reached 92.5%, surpassing the industry average of 90% [15] Hospital Operations - Sichuan Friendship Hospital generated revenue of 291 million CNY, maintaining stability amid competition [6] - Suzhou Guangci Hospital achieved revenue of 269 million CNY, with a year-on-year growth of 1.69% [7] - The company’s managed hospitals, including Yuncheng Hospital, have seen significant operational improvements, with surgical volumes increasing by 18% [12] Strategic Developments - The acquisition of Changsha Kexin Oncology Hospital enhances the company’s oncology ecosystem and regional presence [10] - The company is focusing on differentiated services and expanding its service ecosystem through partnerships and AI integration [9]